This document is an annex to the European Commission guideline on Excipients in the labelling and package leaflet of medicinal products for human use.
It contains a list of excipients with a known action or effect, which must appear on the labelling of medicines in the European Union (EU), and the information which should appear in the package leaflet.
Each revision of this annex is effective from its date of publication.
For authorised medicines, marketing authorisation holders should use the first opportunity to implement any revised wording in the package leaflet.
For medicines with no foreseeable regulatory submissions, marketing authorisation holders should submit a type IB variation within 3 years of the revision date of the relevant excipient…
